Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. announced positive interim data from its Phase 3 open-label upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI). With 8 participants enrolled (halfway to full enrollment), 6 have met the primary endpoint of at least 50% reduction in intravenous glucose requirements, and all were able to discontinue IV glucos…